Yang Qin-tai, Huang Xue-kun, Li Peng, Chen Yu-lian, Zhang Ge-hua
Department of Otorhinolaryngology, SUN Yat-sen University, Guangzhou, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Dec;46(12):992-7.
To investigate the distribution and clonality of T cell receptor (TCR) Vγ and Vδ subfamily in peripheral blood of patients with allergic rhinitis before and after 1 year treatment with immunotherapy.
The specific IgE and the complementary determinant region 3 (CDR3) of TCR V γ (I-III) and Vδ(1-8) subfamily genes in mononuclear cells were amplified from 10 effective cases of allergic rhinitis before and after 1 year treatment with immunotherapy, to observe the distribution and utilization of TCR Vγ and Vδ repertoire. The positive PCR products were further labeled with RT-PCR and analyzed by gene scan technique to determine the CDR3 size and evaluate the clonality of the detectable TCR Vγ and Vδ T cells. Peripheral blood of 10 healthy adults served as controls.
All symptoms were significantly improved after 1 year specific immunotherapy, but no changes were seen in specific IgE [(22.89 ± 9.60) kU/L before treatment, (19.62 ± 7.63) kU/L after treatment, Z = 1.051, P > 0.05]. No statistically significant differences of expression levels of the TCR Vγ I-III subfamily genes were found between patients with allergic rhinitis normal control group (t value were -0.679, -0.516, -0.808, all P > 0.05), but significantly decreased after 1 year treatment. There were statistically significant differences of expression levels of the TCR VγI-II subfamily genes before and after treatment (t value were -2.904, -2.217, all P < 0.05). 5.30 ± 0.82, 4.90 ± 0.57 and 5.20 ± 1.40 out of TCR Vδ (1-8) subfamilies were selectively expressed in T cells in patients with allergic rhinitis before and after 1 year treatment and normal control group, predominantly for TCR Vδ 1, 2, 3 and 6. The TCR Vδ 6 subfamily was found to have statistically significant differences in these groups (Fisher's Exact Test, P < 0.05). Compared with the normal control group and the allergic rhinitis group before treatment, a significant higher frequency of Vδ 6 oligoclonal was identified in T cells in patients with allergic rhinitis after 1 year treatment.
There was difference in the expression levels of the TCR Vγ I-III subfamily genes and distribution and clonality of TCR Vγ and Vδ subfamily T cells in peripheral blood of patients with allergic rhinitis before and after 1 year treatment. Specific immunotherapy can be effective in alleviation of the symptom in patients with allergic rhinitis during the early stage, possibly by inducing TCR γδ T cells, especially the TCR Vδ6 subfamily, and possibly no significant relativity between symptom and specific IgE.
研究变应性鼻炎患者免疫治疗1年前、后外周血T细胞受体（TCR）Vγ和Vδ亚家族的分布及克隆性。
从10例免疫治疗1年前、后的变应性鼻炎有效病例的单核细胞中扩增特异性IgE及TCR Vγ（Ⅰ-Ⅲ）和Vδ（1-8）亚家族基因的互补决定区3（CDR3），观察TCR Vγ和Vδ库的分布及利用情况。对阳性PCR产物进行反转录PCR标记，采用基因扫描技术分析，确定CDR3大小，评估可检测到的TCR Vγ和Vδ T细胞的克隆性。选取10名健康成年人的外周血作为对照。
特异性免疫治疗1年后所有症状均显著改善，但特异性IgE无变化[治疗前为（22.89±9.60）kU/L，治疗后为（19.62±7.63）kU/L，Z=1.051，P>0.05]。变应性鼻炎患者与正常对照组TCR VγⅠ-Ⅲ亚家族基因表达水平差异无统计学意义（t值分别为-0.679、-0.516、-0.808，均P>0.05），但治疗1年后显著降低。治疗前后TCR VγⅠ-Ⅱ亚家族基因表达水平差异有统计学意义（t值分别为-2.904、-2.217，均P<0.05）。变应性鼻炎患者治疗1年前、后及正常对照组TCR Vδ（1-8）亚家族中分别有5.30±0.82、4.90±0.57和5.20±1.40在T细胞中选择性表达，主要为TCR Vδ1、2、3和6。TCR Vδ6亚家族在这些组间差异有统计学意义（Fisher确切概率法，P<0.05）。与正常对照组及治疗前变应性鼻炎组相比，治疗1年后变应性鼻炎患者T细胞中Vδ6寡克隆频率显著升高。
变应性鼻炎患者免疫治疗1年前、后外周血TCR VγⅠ-Ⅲ亚家族基因表达水平及TCR Vγ和Vδ亚家族T细胞分布和克隆性存在差异。特异性免疫治疗可能通过诱导TCRγδ T细胞，尤其是TCR Vδ6亚家族，在早期对变应性鼻炎患者的症状缓解有效，且症状与特异性IgE可能无明显相关性。
